References
Memorial Sloan Kettering Cancer Center. Drug abacus. http://www.drugabacus.org/. Accessed 18 Febr 2017.
Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–34.
Burwell SM. Setting value-based payment goals: HHS efforts to improve U.S. health care. N Engl J Med. 2015;372(10):897–9.
Lichtenberg F, Philipson T. The dual effects of intellectual property regulations: within and between patent competition in the US Pharmaceutical Industry. J Law Econ. 2002;45(Suppl 2):643–72.
Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. Authorized generic drugs, price competition, and consumers’ welfare. Health Aff (Millwood). 2007;26(3):790–9.
Federal Trade Commission. Emerging health care issues: follow-on biologic drug competition. Federal trade commission report. June 2009. Washington, DC: Federal Trade Commission; 2009.
Lu Y, Penrod JR, Sood N, Woodby S, Philipson T. Dynamic cost-effectiveness of oncology drugs. Am J Manage Care. 2012;18(11):S249–56.
Goldman D, Lakdawalla D, Baumgardner J, Linthicum M. Are biopharmaceutical budget caps good public policy? Econ Voice. 2016;13(1):27–42. doi:10.1515/ev-2014-0012.
Philipson TJ, Jena AB. Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. Forum Health Econ Policy. 2006;9(2):3. doi:10.2202/1558-9544.1005.
Lakdawalla DN, Sun EC, Jena AB, Reyes CM, Goldman DP, Philipson TJ. An economic evaluation of the war on cancer. J Health Econ. 2010;29(3):333–46.
Antonanzas F, Terkola R, Postma M. The value of medicines: a crucial but vague concept. Pharmacoeconomics. 2016;34(12):1227–39.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.
Kunkle F. Alzheimer’s caregivers likely to spend more than $50,000 a year. Washington Post. 30 September 2015.
Grant M, Sun V, Fujinami R, et al. Family caregiver burden, skills preparedness, and quality of life in non-small cell lung cancer. Oncol Nurs Forum. 2013;40(4):337–46.
Gridelli C, Ferrara C, Guerriero C, et al. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol. 2007;2(6):475–80.
Fujinami R, Sun V, Zachariah F, Uman G, Grant M, Ferrell B. Family caregivers’ distress levels related to quality of life, burden, and preparedness. Psychooncology. 2015;24(1):54–62.
Grunfeld E, Coyle D, Whelan T, et al. Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ. 2004;170(12):1795–801.
Hoefman RJ, Van Exel J, Brouwer WBF. Measuring care-related quality of life of caregivers for use in economic evaluations: carerqol tariffs for Australia, Germany, Sweden, UK, and US. Pharmacoeconomics. 2017;35(4):469–78.
Krol M, Papenburg J, van Exel J. Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies. Pharmacoeconomics. 2015;33(2):123–35.
Elwert F, Christakis NA. The effect of widowhood on mortality by the causes of death of both spouses. Am J Public Health. 2008;98(11):2092–8.
Christakis NA, Allison PD. Mortality after the hospitalization of a spouse. N Engl J Med. 2006;354(7):719–30.
Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24(4):751–73.
Thornton Snider J, Romley JA, Vogt WB, Philipson TJ. The option value of innovation. Forum Health Econ Policy. 2012;15(2):18.
Sanchez Y, Penrod JR, Qiu XL, Romley J, Thornton Snider J, Philipson T. The option value of innovative treatments in the context of chronic myeloid leukemia. Am J Manag Care. 2012;18(11 Suppl):S265–71.
Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood). 2012;31(4):676–82.
Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172–7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Funding was provided by Pfizer, Inc., to Precision Health Economics (PHE) for the conduct of this research.
Conflict of interest
Dr Philipson is a cofounder of and consultant to PHE, a health economics consultancy to the life science industry. Dr Philipson holds stock in PHE’s parent company, Precision Medicine Group. Dr Kamal-Bahl is an employee and shareholder of Pfizer, Inc. Dr Jena is a consultant to PHE and reports receiving previous consulting fees unrelated to this work from Pfizer, Inc., Hill Rom Services, Inc., Bristol Myers Squibb, Novartis Pharmaceuticals, Vertex Pharmaceuticals and PHE.
Rights and permissions
About this article
Cite this article
Philipson, T.J., Kamal-Bahl, S. & Jena, A.B. Defining Value: The Need for a Longer, Broader View. PharmacoEconomics 35, 669–672 (2017). https://doi.org/10.1007/s40273-017-0503-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-017-0503-7